Friday 6 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue: +41.2%
EPS: −3.67%
Free cash flow: +79.0%

Quarter to September 2026, against a year earlier

160.47 5.58 −3.36%

Follow NBIX

Alert me

Market cap: $16.2B
P/E: 23.0×
Fwd P/E: 20.6×
Dividend yield: —
F-score: 7/9
Altman Z: 7.80
Beneish M: −2.64
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Neurocrine Biosciences, Inc. (NBIX) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Neurocrine Biosciences, Inc. (NBIX) trades at a price to free cash flow of 15.7×. Over the past ten years it has ranged from 0.0× (June 2018) to 17,766× (April 2019); the current reading is higher than 31% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 16.3× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/NBIX/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Neurocrine Biosciences, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/NBIX/metrics/price-to-free-cash-flow">Neurocrine Biosciences, Inc. (NBIX) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	18.8×	(23.36%)
FY2024	24.6×	(30.90%)
FY2023	35.6×	(0.10%)
FY2022	35.6×	3.07%
FY2021	34.6×	(15.71%)
FY2020	41.0×	(44.90%)
FY2019	74.4×	(11.50%)
FY2018	84.1×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	Price to free cash flow	Change
Sep 2026	13.9×	(29.13%)
Jun 2026	19.6×	22.79%
Mar 2026	15.9×	(15.50%)
Dec 2025	18.8×	(19.88%)
36 more quarters	Free account

Against its own ten years

Low 0.0× High 17,766×

Ten-year median 27.2×

Current reading's percentile 31

Company	Price to free cash flow
HLN Haleon PLC Sponsored ADR compare	9.2×
VTRS Viatris Inc. compare	10.7×
ZTS Zoetis Inc. compare	14.7×
NBIX Neurocrine Biosciences, Inc.	15.7×
UTHR United Therapeutics Corporation compare	28.0×
ALKS Alkermes plc compare	32.8×
ELAN Elanco Animal Health Incorporated compare	33.2×
KNSA Kiniksa Pharmaceuticals International, plc compare	35.1×
RDY Dr. Reddy's Laboratories Ltd compare	126×
Drug Manufacturers Specialty & Generic industry median	16.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Neurocrine Biosciences, Inc. (NBIX) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on NBIX

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on NBIX

Stockrow Weekly